Aakha
Frisco, US · Founded 2022 · Delaware corporation · 8 employees on LinkedIn · 1 known investors
Find your way into Aakha
548 people in our graph share verified history with the Aakha team — schools, employers, funds. One of them is your warm intro.
Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.
Founders & leadership
Aakha was founded in 2022 by Hemanta Baruah.

Board

Investors · 1
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2024
▶$750KraisedJul 2024 · 1 investors · BiotechnologyRule 506(b)
- Christopher PachecoDirector
- Hemanta BaruahExecutive Officer, Director
- Errik AndersonDirector
- George Robert Mabry IIIDirector
- Offering amount
- $5M
- Amount sold
- $750K
- Proceeds to insiders
- $100K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapCompanies competing with Aakha for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aakha do?
- Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.
- Who founded Aakha?
- Aakha was founded by Hemanta Baruah in 2022.
- Who are Aakha's investors?
- Aakha's investors include 82VS.
- How much funding has Aakha raised?
- Aakha has disclosed $750K raised across 1 round.
- Where is Aakha headquartered?
- Aakha is headquartered in Frisco, US.





